Skip to main content
SpringerLink
Log in

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Although proton pump inhibitors (PPIs) have been used widely, acid-related diseases are still associated with a huge burden on the health care system. Recently, the efficacy and safety of a new acid suppressant named vonoprazan in the treatment of acid-related diseases have been evaluated by a series of studies. As a novel potassium-competitive acid blocker, vonoprazan may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection in Japan. The healing rate of GERD and gastric ulcers by vonoprazan is more than 95 and 90%, respectively; also, it is effective in curing PPI-resistant GERD. It increases H. pylori eradication rate to more than 88% as part of both first-line and second-line therapy. It is also effective in the eradication of clarithromycin-resistant H. pylori strains. All of these short-term studies show vonoprazan is safe and well-tolerated. As a safe and effective acid inhibitor, vonoprazan might be a novel alternative in the treatment of acid-related diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295–314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Ganser AL, Forte JG. K+-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochim Biophys Acta.. 1973;307:169–180.

    Article  CAS  PubMed  Google Scholar 

  3. Malfertheiner P. Guidelines for the diagnosis and treatment of H. pylori infection. MMW Fortschr Med. 2003;145:42–45.

    CAS  PubMed  Google Scholar 

  4. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30.

    Article  CAS  PubMed  Google Scholar 

  5. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:e14.

    Article  Google Scholar 

  6. Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects–a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719–730.

    Article  CAS  PubMed  Google Scholar 

  7. Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55:3415–3422.

    Article  CAS  PubMed  Google Scholar 

  8. Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment. Pharmacol. Ther.. 2000;14:1383–1401.

    Article  CAS  PubMed  Google Scholar 

  9. Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2012;17:177–182.

    Article  CAS  PubMed  Google Scholar 

  10. Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75:439–443.

    Article  CAS  PubMed  Google Scholar 

  11. Keeling DJ, Taylor AG, Schudt C. The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+ + K+)-ATPase. J Biol Chem. 1989;264:5545–5551.

    CAS  PubMed  Google Scholar 

  12. Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015;42:1315–1326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25–35.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412–420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–238.

    Article  CAS  PubMed  Google Scholar 

  16. Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446–4456.

    Article  CAS  PubMed  Google Scholar 

  18. Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12–22.

    Article  CAS  PubMed  Google Scholar 

  20. Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048–1059.

    Article  CAS  PubMed  Google Scholar 

  21. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol.. 2013;108:308–328. (quiz 329).

    Article  PubMed  Google Scholar 

  22. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871–880.

    Article  PubMed  Google Scholar 

  23. Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685–695.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240–251.

    Article  CAS  PubMed  Google Scholar 

  25. Iwakiri K, Umegaki E, Hiramatsu N, et al. Su1119 A Phase 3, randomized, double-blind, multicenter study to evaluate the dose-response relationships of acid-inhibitory effect of vonoprazan (20 mg, 40 mg) in patients with proton pump inhibitor-resistant erosive esophagitis [Abstract]. Gastroenterology. 2016;150:S475–S475.

    Article  Google Scholar 

  26. Hanada Y, Hoshino S, Hoshikawa Y, et al. Su1120 efficacy of vonoprazan on PPI-resistant reflux esophagitis [Abstract]. Gastroenterology. 2016;150:S475–S475.

    Article  Google Scholar 

  27. Koike T, Saito M, Kikuchi H, et al. Vonoprazan reduces the GERD symptoms in the symptom index positive PPI-refractory NERD. J Gastroenterol Hepatol. 2016;31:21.

    Article  Google Scholar 

  28. Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep. 2017;6:175–180.

    Article  PubMed  Google Scholar 

  29. Maruoka D, Arai M, Kasamatsu S, et al. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score-matching analysis. Dig Endosc. 2017;29:57–64.

    Article  PubMed  Google Scholar 

  30. Kagawa T, Iwamuro M, Ishikawa S, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther. 2016;44:583–591.

    Article  CAS  PubMed  Google Scholar 

  31. Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial. Dig Endosc. 2017;29:576–583.

    Article  PubMed  Google Scholar 

  32. Takahashi K, Sato Y, Kohisa J, et al. Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers. World J Gastrointest Endosc. 2016;8:716–722.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Hiroyuki K, Hiroya U, Akihito N, et al. # 1505 Vonoprazan versus rabeprazole for the healing effect of gastric ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. J Gastroenterol Hepatol. 2016;31:291.

    Google Scholar 

  34. Mizokami Y, Ashida K, Soen S, et al. Tu1054 TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a Phase 3 trial. Gastroenterology. 2014;146:S739.

    Article  Google Scholar 

  35. Kawai T, Ashida K, Mizokami Y, et al. Tu1055 TAK-438 versus lansoprazole 15 mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a Phase 3 trial [Abstract]. Gastroenterology. 2014;146:S739.

    Article  Google Scholar 

  36. Sakurai Y, Shiino M, Horii S, et al. Pharmacokinetic drug–drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a Phase 2, open-label, study in healthy Japanese men. Clin Drug Invest. 2017;37:39–49.

    Article  CAS  Google Scholar 

  37. Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers—results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45:240–252.

    Article  CAS  PubMed  Google Scholar 

  38. Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949–956.

    Article  CAS  PubMed  Google Scholar 

  39. Shinozaki S, Nomoto H, Kondo Y, et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci. 2016;32:255–260.

    Article  PubMed  Google Scholar 

  40. Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis. 2016;17:670–675.

    Article  CAS  PubMed  Google Scholar 

  41. Noda H, Noguchi S, Yoshimine T, et al. A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis. 2016;25:283–288.

    PubMed  Google Scholar 

  42. Yamada S, Kawakami T, Nakatsugawa Y, et al. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2016;7:550–555.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Murakami K, Sakurai Y, Shiino M, Funao N, Nishinura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439–1446.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Maruyama M, Kubota D, Miyajima M, et al. Tu2083 A randomized controlled trial comparing the first-line eradication rate using vonoprazan or PPI for Helicobacter pylori infectious gastritis [Abstract]. Gastroenterology. 2016;150:S1269–S1269.

    Article  Google Scholar 

  45. Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T. Helicobacter pylori Eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci. 2016;61:3215–3220.

    Article  CAS  PubMed  Google Scholar 

  46. Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a Phase 1, open-label, randomized, crossover study. Adv Ther. 2016;33:1519–1535.

    Article  CAS  PubMed  Google Scholar 

  47. Yamasaki T, Owari M, Amano Y, et al. High dose CAM with vonoprazan (P-CAB) plus AMX regimen is the strongest H. pylori eradication triple therapy regimens to improve success rate of CAM based regimens. J Gastroenterol Hepatol. 2016;31:61.

    Google Scholar 

  48. Graham DY. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut. 2017;66:384–386.

    PubMed  Google Scholar 

  49. Furuta T, Shu S, Ichikawa H, et al. Tu1333 dual therapy with vonoprazan and amoxicillin is as effective as standard PPI-based triple therapy with amoxicillin and clarithromycin or metronidazole in Japan [Abstract]. Gastroenterology. 2016;150:S877–S877.

    Google Scholar 

  50. Sato Yu, Yamamoto K, Onishi Y, et al. Efficacy of the vonoprazan (VPZ)-based second line therapy for Helicobacter pylori (HP) eradication. J Gastroenterol Hepatol. 2016;31:67.

    Google Scholar 

  51. Okimoto K, Arai M, Kasamatsu S, et al. Su1027 efficacy of sitafloxacin-based triple therapy for eradication-refractory Helicobacter pylori and salvage therapy with the new potassium-competitive acid blocker vonoprazan [Abstract]. Gastroenterology. 2016;150:S447–S447.

    Article  Google Scholar 

  52. Kawashima K, Ishihara S, Kinoshita Y. Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. Dig Liver Dis. 2016;48:688–689.

    Article  PubMed  Google Scholar 

  53. Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017;22:e12374.

    Article  Google Scholar 

  54. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106–114. https://doi.org/10.1111/apt.14130.

    Article  CAS  PubMed  Google Scholar 

  55. Dong SQ, Singh TP, Wei X, Yao H, Wang HL. A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion? Helicobacter. 2017;22. https://doi.org/10.1111/hel.12438.

  56. Fraser AG. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. Aliment Pharmacol Ther. 2017;46:550–551.

    Article  CAS  PubMed  Google Scholar 

  57. Jung YS, Kim EH, Park CH. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors’ reply. Aliment Pharmacol Ther. 2017;46:551–552.

    Article  CAS  PubMed  Google Scholar 

  58. Me P, Dj K. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Invest Drugs. 2005;14:411–421.

    Article  Google Scholar 

  59. Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franzén S. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:1385–1391.

    Article  CAS  PubMed  Google Scholar 

  60. Kamiya K, Nishio E, Horio A, Tokura Y. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. J Dermatol. 2016;43:340–341.

    Article  PubMed  Google Scholar 

  61. Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus. Drugs. 2017;77:547–561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Abe K, Tani K, Fujiyoshi Y. Systematic comparison of molecular conformations of H+, K+-ATPase reveals an important contribution of the A-M2 linker for the luminal gating. J Biol Chem. 2014;289:30590–30601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

No financial support was received for this work from any company. This study was supported by the National Nature Science Foundation of China (no. 81330012).

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, 107 Wenhuaxi Road, Jinan, 250012, Shandong Province, China

    Xiaoxiao Yang, Yueyue Li, Yiyuan Sun, Mingming Zhang, Chuanguo Guo, Iqtida Ahmed Mirza & Yan-Qing Li

Authors
  1. Xiaoxiao Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yueyue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yiyuan Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mingming Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chuanguo Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Iqtida Ahmed Mirza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yan-Qing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan-Qing Li.

Ethics declarations

Conflict of interest

No conflict of interest or financial ties to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, X., Li, Y., Sun, Y. et al. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Dig Dis Sci 63, 302–311 (2018). https://doi.org/10.1007/s10620-017-4866-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-017-4866-6

Keywords

Search

Navigation